Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after US regulators cleared the treatment.
Cambridge, Massachusetts-based Biogen had been under pressure to divulge the full details from the trials, which ultimately produced conflicting results after being halted early. One study suggested that the treatment, which removes a plaque called amyloid from the brain, could slow the progression of Alzheimer’s. The other did not. The mixed results led to intense debate about whether the drug would provide patients with much benefit.